Q32 Bio Reports Positive Clinical Progress for Bempikibart in Alopecia Areata with 36-Week Data Expected Mid-2026
Key Insights
Q32 Bio completed enrollment of 33 patients in Part B of the SIGNAL-AA Phase 2a trial evaluating bempikibart for severe alopecia areata (search), with 36-week topline data expected in mid-2026.
The company achieved steady-state drug concentrations nine weeks earlier than in Part A due to an optimized loading regimen, potentially enabling earlier clinical responsiveness.
Q32 Bio secured financial runway through Q4 2027 via a $10.5 million registered direct offering and the strategic sale of ADX-097 to Akebia Therapeutics for $12 million upfront.
Q32 Bio has completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial, positioning the company to deliver pivotal 36-week topline results for bempikibart in alopecia areata (search) by mid-2026. The biotechnology company increased the trial size to 33 patients based on patient demand and is observing emerging signs of clinical activity in the ongoing study.
Enhanced Dosing Strategy Shows Promise
The Part B portion of the SIGNAL-AA Phase 2a trial is evaluating bempikibart, a fully human anti-IL-7Rα (search) antibody designed to re-regulate adaptive immune function by blocking IL-7 and TSLP (search) signaling, in patients with severe or very severe alopecia areata (search). The study includes patients with a maximum duration of current episode of four years, who will be treated with bempikibart for 36 weeks with follow-up extending to 52 weeks.
The optimized dosing regimen includes an initial loading phase of 200mg bempikibart administered weekly for four doses, followed by maintenance dosing of 200mg every other week over a 32-week period. According to preliminary pharmacokinetic data, this loading regimen achieves steady-state drug concentrations at least nine weeks earlier compared to Part A of the clinical trial, which may have the potential to induce earlier responsiveness.
Efficacy will be evaluated based on mean percentage change from baseline in Severity of Alopecia Tool (SALT) scores and the proportion of subjects achieving various relative and absolute SALT improvements at week 36. The trial is intended to support advancement into pivotal trials upon completion, pending review of the results.
Regulatory Recognition and Market Need
The FDA has granted Fast Track designation for bempikibart in alopecia areata (search) to expedite development and review processes. This regulatory milestone underscores the significant unmet medical need in alopecia areata, which affects approximately 700,000 people in the United States and has a life-altering impact on patients with limited current treatment options.
"There remains significant need for safer and more durable therapies in AA, and we believe bempikibart has the potential to transform the treatment paradigm," said Jodie Morrison, Chief Executive Officer of Q32 Bio. The company is encouraged by promising pharmacokinetic data and emerging signs of clinical activity observed in Part B of the trial.
Strategic Portfolio Focus and Financial Positioning
Q32 Bio has strategically refocused its operations on advancing bempikibart for alopecia areata (search) through several key transactions. The company completed the sale of its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics in December 2025. Under the agreement terms, Q32 Bio received $7 million at signing, with an additional $3 million due at the 6-month anniversary and $2 million payable upon the earlier of achieving a milestone or the end of 2026, totaling $12 million in upfront and near-term payments.
The asset sale positions Q32 Bio to receive up to $592 million upon achievement of certain development, regulatory and commercial milestones, plus tiered royalties on potential future sales ranging from low single-digit to mid-teen percentages.
In February 2026, Q32 Bio completed a $10.5 million registered direct offering of 1,666,679 shares of common stock and pre-funded warrants. The company reported cash and cash equivalents of $48.3 million as of December 31, 2025, which combined with proceeds from the offering and guaranteed milestone payments from the ADX-097 sale, is expected to provide financial runway into the fourth quarter of 2027.
Operational Efficiency and Long-term Follow-up
The company has demonstrated operational efficiency with research and development expenses decreasing to $19.2 million for the full year 2025, compared to $48.1 million in 2024. This reduction reflects lower bempikibart development costs, discontinuation of the ADX-097 program, and reduced personnel-related costs.
Part A of the SIGNAL-AA trial continues through an open-label extension (OLE) initiated in April 2025, enabling longer-term follow-up of patients. The continued emergence of bempikibart data suggests a remittive effect and durable responses in long-term follow-up, with strong patient demand for continued dosing supporting the extension study.
Q32 Bio's IL-7 and TSLP (search) pathway targeting approach addresses pathways that have been genetically and biologically implicated in driving T cell-mediated pathological processes in numerous autoimmune diseases, positioning bempikibart as a potentially transformative therapy for alopecia areata (search) and other autoimmune conditions.